Nov 16 (Reuters) – Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease.
The drug, Povofortay, chemically known as povorcitinib, was approved for adults with moderate-to-severe hidradenitis suppurativa who have responded inadequately to, or cannot take, anti-tumor necrosis factor therapies.
The approval marks a potential new growth driver for Incyte, as it looks to expand beyond its flagship blood cancer drug Jakafi and strengthen its immunology and inflammation portfolio.
Povorcitinib is also under review by the US Food and Drug Administration for treating moderate-to-severe hidradenitis suppurativa, with a regulatory decision expected in the first quarter of 2027, Incyte said.
Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful nodules, abscesses and scarring that can significantly affect patients’ quality of life.
The EU approval was based on data from two late-stage studies, which showed that Povofortay met the main goal of improving symptoms at 12 weeks and delivered durable responses through 54 weeks.
Incyte said up to 71.4% of patients achieved a key measure of clinical response after 54 weeks of treatment, while the drug’s safety profile remained consistent with earlier studies.
Povorcitinib works by blocking JAK1, a protein involved in the inflammation that leads to painful abscesses and nodules.
Treatment options for the condition are limited and include mainly injectable drugs.
There are currently three FDA-approved treatments for the condition: AbbVie’s Humira, Novartis’ Cosentyx and UCB’s Bimzelx.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini Ganguli)

